scholarly journals Metabolic Dysfunction-Associated Fatty Liver Disease Better Predicts Incident Cardiovascular Disease

Gut and Liver ◽  
2021 ◽  
Author(s):  
Seogsong Jeong ◽  
Yun Hwan Oh ◽  
Seulggie Choi ◽  
Jooyoung Chang ◽  
Sung Min Kim ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Metabolic Dysfunction ◽  
Incident Cardiovascular Disease

scholarly journals Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease

Medicine ◽  
2017 ◽  
Vol 96 (18) ◽  
pp. e6712 ◽  
Author(s):  
Hashimoto Yoshitaka ◽  
Masahide Hamaguchi ◽  
Takao Kojima ◽  
Takuya Fukuda ◽  
Akihiro Ohbora ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Nonalcoholic Fatty Liver ◽  
Incident Cardiovascular Disease

scholarly journals Association of Hepatic Steatosis and Metabolic Dysfunction With Incident Cardiovascular Disease: A Nationwide Cohort Study

2021 ◽  
Author(s):  
Seogsong Jeong ◽  
Yun Hwan Oh ◽  
Seulggie Choi ◽  
Jooyoung Chang ◽  
Sung Min Kim ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Cohort Study ◽  
Liver Disease ◽  
Fatty Liver ◽  
Hepatic Steatosis ◽  
National Health ◽  
Fatty Liver Disease ◽  
Health Examination ◽  
Metabolic Dysfunction ◽  
Cvd Risk

Abstract Background/purpose: Metabolic dysfunction (MD)-associated fatty liver disease (MAFLD) is new clearer nomenclature with positive diagnostic criteria on the basis of hepatic steatosis and MD, involving exclusion criteria for nonalcoholic fatty liver disease (NAFLD).Methods: This retrospective cohort study included 333,389 participants who received health examination between 2009 and 2010 from the Korean National Health Insurance Service database. Hepatic steatosis was defined using the Korean National Health and Nutrition Examination Survey-derived NAFLD scoring system. Participants were followed over 5-6 years from the index date of health examination to 31 December 2015 for cardiovascular disease (CVD). The Cox proportional hazards regression was adopted to determine adjusted hazard ratio (aHR) with 95% confidence interval (CI) for CVD according to the presence of hepatic steatosis, MD, and MAFLD.Results: This study included 179,437 men and 153,952 women with a median age of 57 years. Hepatic steatosis with MD (aHR, 2.00; 95% CI, 1.89-2.13) and without MD (aHR, 1.30; 95% CI, 1.10-1.54) significantly increased the risk of CVD compared to no steatosis without MD (reference). However, steatosis revealed no significant difference in the risk of CVD compared to no steatosis among participants with one metabolic dysfunction (aHR, 1.09; 95% CI, 0.91-1.30). In participants with steatosis, the presence of one and ≥2 metabolic dysfunctions had aHR of 1.25 (95% CI, 0.87-1.79) and 1.71 (95% CI, 1.22-2.41) compared to no MD, respectively.Conclusion: MAFLD was significantly associated with increased CVD risk and had better predictive performance for CVD risk compared to hepatic steatosis or metabolic dysfunction alone.

scholarly journals Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan

2021 ◽  
Author(s):  
Masato Yoneda ◽  
Takuma Yamamoto ◽  
Yasushi Honda ◽  
Kento Imajo ◽  
Yuji Ogawa ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Incidence Rates ◽  
Point Of View ◽  
Metabolic Dysfunction ◽  
Nonalcoholic Fatty Liver ◽  
Claims Database

Abstract Background Nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction associated fatty liver disease (MAFLD) have important associations with cardiovascular disease (CVD). The main objective of this study was to compare the frequency of incidence rate of CVD in the NAFLD or MAFLD patients utilizing a large claims database. Methods Using the JMDC database from April 2013 to March 2019, we retrospectively analyzed data for 1,542,688 and 2,452,949 people to estimate the relationship between CVD and NAFLD, MAFLD, respectively. Results The incidence rates of CVD were 0.97 (95% CI 0.94–1.01) and 2.82 (95% CI 2.64–3.01) per 1000 person-years in the non-NAFLD and NAFLD groups, respectively, and 1.01 (95% CI 0.98–1.03) and 2.69 (95% CI 2.55–2.83) per 1000 person-years in the non-MAFLD and MAFLD groups, respectively. The overall prevalence of hypertriglyceridemia and diabetes mellitus (DM) was 13.1, and 4.2%, respectively, in the non-NAFLD group and 63.6, and 20.2%, respectively, in the NAFLD group. The overall prevalenceof hypertriglyceridemia and DM was 13.6 and 4.3%, respectively, in the non-MAFLD group and 64.1, and 20.6%, respectively, in the MAFLD group. HRs for CVD increased with hypertriglyceridemia and DM. Conclusions Results indicated that incident rate of CVD increased with NAFLD/MAFLD; the complication rate of DM and hypertriglyceridemia among NAFLD/MAFLD patients is high and may affect the development of CVD.

Sign in / Sign up

Export Citation Format

Share Document